menu
    • menu
    [{"orgOrder":0,"company":"ImaginAb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"IAB56","moa":"Alpha-V-beta-6 integrin","graph1":"Oncology","graph2":"IND Enabling","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImaginAb \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"ImaginAb \/ Undisclosed"},{"orgOrder":0,"company":"ImaginAb","sponsor":"DynamiCure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"DCBY02","moa":"CD93","graph1":"Oncology","graph2":"Phase I","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImaginAb \/ DynamiCure","highestDevelopmentStatusID":"6","companyTruncated":"ImaginAb \/ DynamiCure"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Incendia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"PRTH-101","moa":"DDR1","graph1":"Oncology","graph2":"Preclinical","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImaginAb \/ Incendia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"ImaginAb \/ Incendia Therapeutics"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Bempegaldesleukin","moa":"interleukins: interleukin-2 analogues and derivatives; PEGylated compounds","graph1":"Oncology","graph2":"Phase III","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImaginAb \/ ImaginAb","highestDevelopmentStatusID":"10","companyTruncated":"ImaginAb \/ ImaginAb"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Leucid Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Licensing Agreement","leadProduct":"89Zr-crefmirlimab","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImaginAb \/ Leucid Bio","highestDevelopmentStatusID":"4","companyTruncated":"ImaginAb \/ Leucid Bio"},{"orgOrder":0,"company":"ImaginAb","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImaginAb \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"ImaginAb \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"ImaginAb","sponsor":"TriSalus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ImaginAb \/ TriSalus Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"ImaginAb \/ TriSalus Life Sciences"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Clarity Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Collaboration","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImaginAb \/ Clarity Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ImaginAb \/ Clarity Pharmaceuticals"},{"orgOrder":0,"company":"ImaginAb","sponsor":"ImaginAb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"89-Zr Crefmirlimab Berdoxa","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImaginAb \/ ImaginAb","highestDevelopmentStatusID":"6","companyTruncated":"ImaginAb \/ ImaginAb"},{"orgOrder":0,"company":"ImaginAb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"89-Zr Crefmirlimab Berdoxa","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImaginAb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ImaginAb \/ Undisclosed"},{"orgOrder":0,"company":"ImaginAb","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AZD8853","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImaginAb \/ ImaginAb","highestDevelopmentStatusID":"7","companyTruncated":"ImaginAb \/ ImaginAb"},{"orgOrder":0,"company":"ImaginAb","sponsor":"University of Hull","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Zirconium 89Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImaginAb \/ University of Hull","highestDevelopmentStatusID":"8","companyTruncated":"ImaginAb \/ University of Hull"}]

    Find Clinical Drug Pipeline Developments & Deals by ImaginAb

    Menu

    ImaginAb

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IAB56

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ImaginAb Advances Two Solid Tumor Radiopharmaceutical Therapy (RPT) Candidates Towards Clinical Development

                            Details : IAB56 is a minibody, RPT agent is designed to target integrin avb6, a receptor over-expressed in a broad range of solid cancers underserved by current cancer therapies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 18, 2023

                            Lead Product(s) : IAB56

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LEU011,89Zr-crefmirlimab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Leucid Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with Leucid Bio

                            Details : Under the terms of the agreement, ImaginAb will license and supply clinical doses of ImaginAb's investigational CD8 ImmunoPET tracer, 89Zr crefmirlimab berdoxam, to Leucid for use in its basket study in solid tumors, with LEU011 targeting NKG2DL, Autolog...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            April 12, 2023

                            Lead Product(s) : LEU011,89Zr-crefmirlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Leucid Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zirconium 89Zr

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : University of Hull

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CD8 Minibody Repeatability Study

                            Details : Zirconium 89Zr is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 24, 2023

                            Lead Product(s) : Zirconium 89Zr

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : University of Hull

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : TriSalus Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences

                            Details : Under the agreement, ImaginAb will license and supply clinical doses of investigational CD8 ImmunoPET to TriSalus for use in its clinical trials using its proprietary Pressure-Enabled Drug Delivery method for intravascular delivery of its investigational...

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            November 22, 2022

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : TriSalus Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DCBY02

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : DynamiCure

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ImaginAb Executes License and Supply Agreement for CD8 ImmunoPET Technology with DynamiCure Biotechnology

                            Details : Under the agreement, ImaginAb will license and supply clinical doses of its investigational CD8 ImmunoPET, DCBY02 to DynamiCure Biotechnology for use in its clinical trial.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            November 15, 2022

                            Lead Product(s) : DCBY02

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : DynamiCure

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRTH-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Incendia Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer ...

                            Details : Parthenon will use ImaginAb’s CD8 ImmunoPET imaging agent 89Zr crefmirlimab berdoxam in its Phase 1 trial evaluating its lead compound, PRTH-101, which is expected to begin in 2023.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            November 10, 2022

                            Lead Product(s) : PRTH-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Incendia Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ImaginAb and Roche Have Entered a Clinical Trial Supply Agreement for Provision of Atezolizumab (Tecentriq®)1...

                            Details : ImaginAb announced the launch of its Phase IIb “iPREDICT” trial in January this year, as it continues to develop clinical data to support marketing approval of its investigational CD8 ImmunoPET agent (zirconium Zr 89 crefmirlimab berdoxam).

                            Product Name : Tecentriq

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            June 08, 2022

                            Lead Product(s) : Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZD8853

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanc...

                            Details : AZD8853 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Urinary Bladder Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 31, 2022

                            Lead Product(s) : AZD8853

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 89-Zr Crefmirlimab Berdoxa

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Abramson Cancer Center at Penn Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zr89 + PET Companion Trial

                            Details : 89-Zr Crefmirlimab Berdoxa is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            March 15, 2022

                            Lead Product(s) : 89-Zr Crefmirlimab Berdoxa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Abramson Cancer Center at Penn Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            ImaginAb

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 89-Zr Crefmirlimab Berdoxa

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

                            Details : 89-Zr Crefmirlimab Berdoxa is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            August 19, 2021

                            Lead Product(s) : 89-Zr Crefmirlimab Berdoxa

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth